Chantix
Chantix (Varenicline) is a smoking cessation medication that works by blocking nicotine receptors, thereby reducing cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. New evidence suggests that Chantix is linked to serious cardiovascular, heart disease, stroke and heart attack risk and serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs.
A published report states that users of the smoking cessation drug Varenicline, brand name Chantix, has been linked to an increased risk of cardiovascular events. The study suggests that 1 in every 28 patients receiving Chantix would experience a serious cardiovascular risk such as a stroke or heart attack.
The cardiovascular risks prompted the Food & Drug Administration to issue a warning to physicians in June 2011 that users of Chantix face an increased risk of heart problems such as strokes and heart attacks.
Other analyses revealed that some who have taken Chantix have reported experiencing unusual changes in behavior, become depressed, or had their depression worsen, and had thoughts of suicide or dying. According to media reports, the FDA had received 98 reports of suicide among patients taking Chantix and 188 reports of attempted suicide, and 14 suicides.
Heninger Garrison Davis is currently investigating Chantix lawsuits on behalf of people who have suffered cardiovascular or mental health problems as a result of this medication. If you or a loved one has suffered from a heart attack, stroke, depression or other mental health issues after taking Chantix, please contact us.
